Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium Tc-99m isonitrile glucosamine
- Development stage
- Unknown
- Lead developer
- Beijing Shihong Pharmaceutical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Technetium Tc-99m isonitrile glucosamine (99mTc-CN-DG) is a technetium-labeled glucose derivative developed by Beijing Shihong Pharmaceutical Co., Ltd. as a diagnostic radiopharmaceutical. It is designed for the imaging of malignant tumors, specifically non-small cell lung cancer (NSCLC), using Single Photon Emission Computed Tomography (SPECT). The molecule acts as a glucose analog, entering cells via glucose transporters (primarily GLUT1), which are overexpressed in many cancer types due to increased glycolytic demand (the Warburg effect). Unlike 18F-FDG, which requires PET imaging, 99mTc-CN-DG utilizes the more widely available SPECT technology, potentially providing a more cost-effective and accessible diagnostic tool for tumor metabolic imaging.
- Other names
- 99mTc-isonitrile-glucosamine99mTc-labeled isonitrile glucosamine99mTc-labeled 2-glucosamine isonitrile
02
Targets
GLUT1 (Glucose transporter 1)SLC2A2 (Solute carrier family 2 facilitated glucose transporter member 2)SLC2A3 (Glucose transporter type 3)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)GLUT5 (Glucose transporter 5)
Beyond the preview
Go deeper on technetium Tc-99m isonitrile glucosamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium Tc-99m isonitrile glucosamine.